Prostate Cancer Clinical Trials in Baltimore

Showing 201-220 of 446 trials

COMbination of Bipolar Androgen Therapy and Nivolumab

NCT03554317

Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one novel androgen-receptor targeted therapy (i.e. Abiraterone acetate, Enzalutamide). Up to one taxane agent is permitted.

Castration-resistant Prostate CancerMetastatic Prostate CancerProstate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins45 participantsStarted Sep 2018

San Francisco, California, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States

TERMINATEDPhase 1< 1 mile

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

NCT02995330

Men with progressive metastatic Castration-Resistant Prostate Cancer post first-line treatment with either androgen deprivation therapy alone or androgen deprivation therapy plus docetaxel who have an identified related female donor (mother sister, daughter, second degree relative such as granddaughter or niece) will undergo bone marrow transplantation followed by post-transplant Cytoxan (PT/Cy) and testosterone.

Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3 participantsStarted Feb 2017

Baltimore, Maryland, United States

COMbination of Bipolar Androgen Therapy and Nivolumab

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Trials in Other Cities

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

Behavioral Weight Loss Program for Cancer Survivors in Maryland

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

Streamlined Genetic Testing in Prostate Cancer

A Study of PRT2527 in Participants With Advanced Solid Tumors

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Identification of Clinically Insignificant or Significant Prostate Cancer With the miR Scientific Sentinel™ Platform

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Other Conditions in Baltimore